Welcome to the EASD e-Learning Newsflash, covering the 61st Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria! Embedded amongst leading scientists, clinicians, and people living with diabetes, we will be relaying hand-picked scientific highlights to you over the next few day, wherever you’re watching from. This is our Day 1 report. We begin with Professor Robert Wagner from DDZ. He’ll tell us about precision medicine approaches driven by monogenic diabetes subtypes. We should find, for every patient, for every person involved, the right treatment. And it’s a huge task, which can be started from the monogenic angle, but as many presentations also showed, it’s much more complicated, because also there are persons around who have a monogenic mutation which should cause diabetes, but they don’t have diabetes. Previous dogmas are sometimes broken by new data. Someone from Copenhagen, from the Steno Institute did a very nice study with empagliflozin in persons with HNF1A MODY. Previously, empagliflozin was thought to be a no-go for this specific rare diabetes type, but it turns out that if you give empagliflozin for patients with HNF1A MODY, who are not well-managed, who are not well-controlled, you substantially improve the glycaemia from around 10 mmol/l to 8 mmol/l . So not everything, which we think as a given based on our previous biological data, is true in the practice. Next, we’ll talk to the to the Gothenburg-based technology researcher Professor Peter Adolfsson. He will present his highlights from a session that is built around the question: Is there no life outside the CGM matrix now? The symposium actually showed that there are quite large differences depending on country. I listened to three presentations from India. They figure out that CGM metrics can be used to classify persons with diabetes into different types of diabetes or different even types of medical treatments. And an even more interesting presentation was regarding physical exercise and the use of CGM in adolescence where more exercise actually was associated with higher “time in range”, also a bit higher “time below range”. What I would like to recommend as a tip is on Wednesday on the Spotlight Stage. We are going to discuss the importance of new standards on CGM devices. We are going to talk about accuracy, the problem if the system isn’t accurate enough, but also the solution. So please come and visit us, one o’clock. Another area where we’ve seen significant movement recently is screening. We will talk to EASD President Professor Chantal Mathieu, who presented in a symposium on the emerging consensus for population-level screening to detect early-stage type 1 diabetes. We started with the low-hanging fruit, namely a document on monitoring. But now came the more difficult task: How should we screen the general population for early-stage type 1 diabetes? And that was presented today in the EASD for the first time. What we clearly stated is that, if you’ve never screened before for early-stage type 1 diabetes in your region or in your country, a good place to start is with family members or people who are at genetic risk for type 1 diabetes who, for instance, have another autoimmune disease. Organising your screening for the first time in this population is a bit easier, because what we propose is to link it to other activities around the child. But where we want to go in the very near future is the general population. You also spoke about how to effectively communicate results. The big question most likely for families would be: But can type 1 diabetes be delayed? It is crucial to explain to the families why we do this. First reason, why we are screening for an early-stage of type 1 diabetes, is really to find the people, educate them, and thus prevent them from having their diagnosis in a dramatic situation, that is diabetic ketoacidosis. So we are preparing the family for a soft landing. We propose to use language that is accessible to the family, and we give examples of documents that you can already download from the web, for instance, from the EDENT1FI.eu page, from the Fr1da pages, in the US from ASK. But of course, we also do this to be able to eventually delay the progression to clinical type 1 diabetes. And we are now having disease-modifying therapies in our hand, hopefully very soon. And the symposium related to this is on Friday, “Towards arresting type 1 diabetes: breaking results,” at 7:15 in the morning. What can you already tell us about this? Yes, we made an early bird session to accommodate the breaking trials in type 1 diabetes. On the Friday morning, we have the two trials reporting: the MELD-ATG trial and the Ver-A-T1D trial. Both trials in newly diagnosed people with clinical stage 3 type 1 diabetes. One testing different doses of ATG, anti-thymocate globulin, that will be published simultaneously in Lancet, and also the Ver-A-T1D study, where in adults we have tested verapamil as a disease-modifying therapy to see: Can we protect the beta cell? So we’re all very excited for this early bird symposium on arresting type 1 diabetes. Thank you, Madame President. That concludes Day 1 of the EASD e-Learning Newsflash from the 61st Annual Meeting. Join us tomorrow for more scientific highlights.